Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

Anna Boronat; Julian Mateus; Natalia Soldevila-Domenech; Mercè Guerra; Jose Rodríguez-Morató; Carlota Varon; Daniel Muñoz; Francina Barbosa; Juan Carlos Morales; Andreas Gaedigk; Klaus Langohr; Maria Isabel Covas; Clara Pérez-Mañá; Montserrat Fitó; Rachel F. Tyndale; Rafael de la Torre

doi:https://doi.org/10.1016/j.dib.2019.104787

Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

Anna Boronat, Julian Mateus, Natalia Soldevila-Domenech, Mercè Guerra, Jose Rodríguez-Morató, Carlota Varon, Daniel Muñoz, Francina Barbosa, Juan Carlos Morales, Andreas Gaedigk, Klaus Langohr, Maria Isabel Covas, Clara Pérez-Mañá, Montserrat Fitó, Rachel F. Tyndale, Rafael de la Torre^*

^*Corresponding author for this work

Department of Pharmacology, Therapeutics and Toxicology

Research output: Contribution to journal › Article › Research › peer-review

7 Citations (Scopus)

Abstract

Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article “Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial” [1].

Original language	English
Article number	104787
Journal	Data in brief
Volume	27
DOIs	https://doi.org/10.1016/j.dib.2019.104787
Publication status	Published - 12 Nov 2019

Keywords

CYP2A6
CYP2D6
Cardiovascular risk
Endogenous conversion
Hydroxytyrosol
Tyrosol

Access to Document

https://doi.org/10.1016/j.dib.2019.104787

https://ddd.uab.cat/record/227873

Cite this

Boronat, A., Mateus, J., Soldevila-Domenech, N., Guerra, M., Rodríguez-Morató, J., Varon, C., Muñoz, D., Barbosa, F., Morales, J. C., Gaedigk, A., Langohr, K., Covas, M. I., Pérez-Mañá, C., Fitó, M., Tyndale, R. F., & de la Torre, R. (2019). Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans. Data in brief, 27, [104787]. https://doi.org/10.1016/j.dib.2019.104787

@article{fc3915199f3143a3aaa5df9e6a09be31,

title = "Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans",

abstract = "Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article “Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial” [1].",

keywords = "CYP2A6, CYP2D6, Cardiovascular risk, Endogenous conversion, Hydroxytyrosol, Tyrosol",

author = "Anna Boronat and Julian Mateus and Natalia Soldevila-Domenech and Merc{\`e} Guerra and Jose Rodr{\'i}guez-Morat{\'o} and Carlota Varon and Daniel Mu{\~n}oz and Francina Barbosa and Morales, {Juan Carlos} and Andreas Gaedigk and Klaus Langohr and Covas, {Maria Isabel} and Clara P{\'e}rez-Ma{\~n}{\'a} and Montserrat Fit{\'o} and Tyndale, {Rachel F.} and {de la Torre}, Rafael",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s)",

year = "2019",

month = nov,

day = "12",

doi = "https://doi.org/10.1016/j.dib.2019.104787",

language = "English",

volume = "27",

journal = "Data in Brief",

issn = "2352-3409",

publisher = "Elsevier BV",

}

Boronat, A, Mateus, J, Soldevila-Domenech, N, Guerra, M, Rodríguez-Morató, J, Varon, C, Muñoz, D, Barbosa, F, Morales, JC, Gaedigk, A, Langohr, K, Covas, MI, Pérez-Mañá, C, Fitó, M, Tyndale, RF & de la Torre, R 2019, 'Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans', Data in brief, vol. 27, 104787. https://doi.org/10.1016/j.dib.2019.104787

TY - JOUR

T1 - Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

AU - Boronat, Anna

AU - Mateus, Julian

AU - Soldevila-Domenech, Natalia

AU - Guerra, Mercè

AU - Rodríguez-Morató, Jose

AU - Varon, Carlota

AU - Muñoz, Daniel

AU - Barbosa, Francina

AU - Morales, Juan Carlos

AU - Gaedigk, Andreas

AU - Langohr, Klaus

AU - Covas, Maria Isabel

AU - Pérez-Mañá, Clara

AU - Fitó, Montserrat

AU - Tyndale, Rachel F.

AU - de la Torre, Rafael

PY - 2019/11/12

Y1 - 2019/11/12

N2 - Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article “Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial” [1].

AB - Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article “Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial” [1].

KW - CYP2A6

KW - CYP2D6

KW - Cardiovascular risk

KW - Endogenous conversion

KW - Hydroxytyrosol

KW - Tyrosol

UR - http://www.scopus.com/inward/record.url?scp=85075215208&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.dib.2019.104787

DO - https://doi.org/10.1016/j.dib.2019.104787

M3 - Article

AN - SCOPUS:85075215208

SN - 2352-3409

VL - 27

JO - Data in Brief

JF - Data in Brief

M1 - 104787

ER -

Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this